Association ofp53codon 72 polymorphism andMDM2SNP309 with clinical outcome of advanced nonsmall cell lung cancer

p53 Mutations in Human Cancers

1991 • 8,133 citations

Surfing the p53 network

2000 • 6,487 citations

The p53 tumour suppressor gene

1991 • 3,871 citations

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

1992 • 3,110 citations

Amplification of a gene encoding a p53-associated protein in human sarcomas

1992 • 1,959 citations

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

1993 • 1,445 citations

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential

2003 • 1,266 citations

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

2004 • 1,241 citations

Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53

2000 • 1,026 citations

The MDM2 gene amplification database

1998 • 958 citations

Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically

1999 • 712 citations

Functions of the MDM2 oncoprotein

1999 • 556 citations

p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

1993 • 535 citations

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

2000 • 514 citations

Genetic Control of Programmed Cell Death in the Nematode Caenorhabditis Elegans

1994 • 488 citations

Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300

2003 • 458 citations

Ex vivo expansion, adipogenesis and neurogenesis of cryopreserved human bone marrow mesenchymal stem cells

2006 • 426 citations

Accumulation of p53 protein correlates with a poor prognosis in human lung cancer.

1992 • 384 citations

Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer

2007 • 325 citations

The p53 functional circuit

2001 • 302 citations

Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.

2000 • 300 citations

A variation in the structure of the protein-coding region of the human p53 gene

1988 • 286 citations

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo

2004 • 252 citations

Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non–Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy

2001 • 197 citations

Targeting the p53–MDM2 interaction to treat cancer

2004 • 192 citations

A Single Nucleotide Polymorphism in the MDM2 Gene: From a Molecular and Cellular Explanation to Clinical Effect

2005 • 177 citations

Molecular basis for heterogeneity of the human p53 protein.

1986 • 167 citations

Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.

1995 • 160 citations

Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage

1998 • 158 citations

The relationship of p53 immunostaining to survival in carcinoma of the lung

1992 • 147 citations

Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.

1994 • 145 citations

MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation

1997 • 137 citations

Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer.

2000 • 136 citations

The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

2002 • 134 citations

Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture.

1999 • 111 citations

p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

2005 • 102 citations

p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.

2000 • 88 citations

MDM2 SNP309 Polymorphism as Risk Factor for Susceptibility and Poor Prognosis in Renal Cell Carcinoma

2007 • 87 citations

Prognostic significance of p53 andras p21 expression in nonsmall cell lung cancer

1995 • 81 citations

Wild-Type p53 Overexpression and Its Correlation With MDM2 and p14ARF Alterations: An Alternative Pathway to Non–Small-Cell Lung Cancer

2004 • 76 citations

Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer

1995 • 70 citations

TP53 mutation, allelism and survival in non-small cell lung cancer

2005 • 68 citations

The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non–Small Cell Lung Cancer

2005 • 59 citations

MDM2 Polymorphism, Survival, and Histology in Early-Stage Non–Small-Cell Lung Cancer

2007 • 57 citations

Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases

2007 • 41 citations

Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma

2006 • 23 citations

Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers

2006 • 18 citations

MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer.

2000 • 17 citations

Randomized phase II cross-over sequential chemotherapy trial of irinotecan/cisplatin (IP) vs. gemcitabine/vinorelbine (GV) in chemo-naïve patients with stage IIIb/IV non-small cell lung cancer (NSCLC)

2006 • 3 citations